1. Home
  2. ALT vs NNOX Comparison

ALT vs NNOX Comparison

Compare ALT & NNOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • NNOX
  • Stock Information
  • Founded
  • ALT 1997
  • NNOX 2011
  • Country
  • ALT United States
  • NNOX Israel
  • Employees
  • ALT N/A
  • NNOX N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • NNOX Medical Electronics
  • Sector
  • ALT Health Care
  • NNOX Health Care
  • Exchange
  • ALT Nasdaq
  • NNOX Nasdaq
  • Market Cap
  • ALT 292.0M
  • NNOX 248.7M
  • IPO Year
  • ALT N/A
  • NNOX 2020
  • Fundamental
  • Price
  • ALT $3.83
  • NNOX $3.85
  • Analyst Decision
  • ALT Strong Buy
  • NNOX Strong Buy
  • Analyst Count
  • ALT 6
  • NNOX 2
  • Target Price
  • ALT $17.40
  • NNOX $8.50
  • AVG Volume (30 Days)
  • ALT 3.0M
  • NNOX 1.3M
  • Earning Date
  • ALT 08-12-2025
  • NNOX 08-12-2025
  • Dividend Yield
  • ALT N/A
  • NNOX N/A
  • EPS Growth
  • ALT N/A
  • NNOX N/A
  • EPS
  • ALT N/A
  • NNOX N/A
  • Revenue
  • ALT $20,000.00
  • NNOX $11,886,000.00
  • Revenue This Year
  • ALT N/A
  • NNOX $24.12
  • Revenue Next Year
  • ALT $761,880.20
  • NNOX $160.56
  • P/E Ratio
  • ALT N/A
  • NNOX N/A
  • Revenue Growth
  • ALT N/A
  • NNOX 17.36
  • 52 Week Low
  • ALT $2.90
  • NNOX $3.75
  • 52 Week High
  • ALT $11.16
  • NNOX $11.00
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • NNOX 32.78
  • Support Level
  • ALT $3.35
  • NNOX $3.88
  • Resistance Level
  • ALT $3.66
  • NNOX $4.16
  • Average True Range (ATR)
  • ALT 0.19
  • NNOX 0.19
  • MACD
  • ALT 0.07
  • NNOX -0.02
  • Stochastic Oscillator
  • ALT 86.18
  • NNOX 8.44

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About NNOX NANO-X IMAGING LTD

Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.

Share on Social Networks: